Cargando…

Effects of immunisation against PCSK9 in mice bearing melanoma

INTRODUCTION: Inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) is an established modality for the treatment of hypercholesterolaemia. However, the impact of PCSK9 inhibition in other situations such as cancer remains largely unknown. The current study was conducted to study the effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Momtazi-Borojeni, Amir Abbas, Nik, Maryam Ebrahimi, Jaafari, Mahmoud Reza, Banach, Maciej, Sahebkar, Amirhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963136/
https://www.ncbi.nlm.nih.gov/pubmed/32051723
http://dx.doi.org/10.5114/aoms.2020.91291
_version_ 1783488216697929728
author Momtazi-Borojeni, Amir Abbas
Nik, Maryam Ebrahimi
Jaafari, Mahmoud Reza
Banach, Maciej
Sahebkar, Amirhossein
author_facet Momtazi-Borojeni, Amir Abbas
Nik, Maryam Ebrahimi
Jaafari, Mahmoud Reza
Banach, Maciej
Sahebkar, Amirhossein
author_sort Momtazi-Borojeni, Amir Abbas
collection PubMed
description INTRODUCTION: Inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) is an established modality for the treatment of hypercholesterolaemia. However, the impact of PCSK9 inhibition in other situations such as cancer remains largely unknown. The current study was conducted to study the effects of PCSK9 inhibition on cancer endpoints in mice bearing melanoma. MATERIAL AND METHODS: To generate antiPCSK9 antibody in vivo, a nanoliposomal antiPCSK9 vaccine adsorbed to 0.4% Alum adjuvant was subcutaneously injected in C57BL/6 mice four times with bi-weekly intervals. Two weeks after the last immunisation, mice were subcutaneously inoculated with B16F0 melanoma cells. After a tumour mass was palpable (approximately 10 mm(3)), the mice were randomly divided into four groups and subjected to different treatment protocols: (1) PBS (untreated control), (2) vaccine group, (3) the combination of vaccine and a single dose of liposomal doxorubicin (Doxil(®)), and (4) liposomal doxorubicin (positive control) group. To determine therapeutic efficacy, mouse body weight, tumour size, and survival were monitored every three days for 36 days. RESULTS: The nanoliposomal antiPCSK9 vaccine was found to efficiently induce specific antibodies against PCSK9 in C57BL/6 mice, thereby reducing plasma levels and function of PCSK9. Tumour volumes in the vaccinated group were not significantly different from those in the liposomal doxorubicin, combination, and control groups. The time to reach endpoint (TTE) values of the vaccine (28 ±5 days), combination (30 ±6 days), liposomal doxorubicin (34 ±2 days), and control (31 ±2 days) groups were not significantly different, either. Furthermore, the tumour growth delay (TGD) values of the vaccine (–11.5 ±15.4%), liposomal doxorubicin (7.75 ±6.5%), combination (–6 ±20.77%), and control (0 ±7.5) groups were not significantly different. Finally, there was no significant difference between the median survival time and lifespan of the vaccinated versus other tested groups. CONCLUSIONS: The nanoliposomal PCSK9 vaccine did not adversely affect the growth of melanoma tumour nor the survival of tumour-bearing mice.
format Online
Article
Text
id pubmed-6963136
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-69631362020-02-12 Effects of immunisation against PCSK9 in mice bearing melanoma Momtazi-Borojeni, Amir Abbas Nik, Maryam Ebrahimi Jaafari, Mahmoud Reza Banach, Maciej Sahebkar, Amirhossein Arch Med Sci Experimental Research INTRODUCTION: Inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) is an established modality for the treatment of hypercholesterolaemia. However, the impact of PCSK9 inhibition in other situations such as cancer remains largely unknown. The current study was conducted to study the effects of PCSK9 inhibition on cancer endpoints in mice bearing melanoma. MATERIAL AND METHODS: To generate antiPCSK9 antibody in vivo, a nanoliposomal antiPCSK9 vaccine adsorbed to 0.4% Alum adjuvant was subcutaneously injected in C57BL/6 mice four times with bi-weekly intervals. Two weeks after the last immunisation, mice were subcutaneously inoculated with B16F0 melanoma cells. After a tumour mass was palpable (approximately 10 mm(3)), the mice were randomly divided into four groups and subjected to different treatment protocols: (1) PBS (untreated control), (2) vaccine group, (3) the combination of vaccine and a single dose of liposomal doxorubicin (Doxil(®)), and (4) liposomal doxorubicin (positive control) group. To determine therapeutic efficacy, mouse body weight, tumour size, and survival were monitored every three days for 36 days. RESULTS: The nanoliposomal antiPCSK9 vaccine was found to efficiently induce specific antibodies against PCSK9 in C57BL/6 mice, thereby reducing plasma levels and function of PCSK9. Tumour volumes in the vaccinated group were not significantly different from those in the liposomal doxorubicin, combination, and control groups. The time to reach endpoint (TTE) values of the vaccine (28 ±5 days), combination (30 ±6 days), liposomal doxorubicin (34 ±2 days), and control (31 ±2 days) groups were not significantly different, either. Furthermore, the tumour growth delay (TGD) values of the vaccine (–11.5 ±15.4%), liposomal doxorubicin (7.75 ±6.5%), combination (–6 ±20.77%), and control (0 ±7.5) groups were not significantly different. Finally, there was no significant difference between the median survival time and lifespan of the vaccinated versus other tested groups. CONCLUSIONS: The nanoliposomal PCSK9 vaccine did not adversely affect the growth of melanoma tumour nor the survival of tumour-bearing mice. Termedia Publishing House 2019-12-31 /pmc/articles/PMC6963136/ /pubmed/32051723 http://dx.doi.org/10.5114/aoms.2020.91291 Text en Copyright: © 2019 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Experimental Research
Momtazi-Borojeni, Amir Abbas
Nik, Maryam Ebrahimi
Jaafari, Mahmoud Reza
Banach, Maciej
Sahebkar, Amirhossein
Effects of immunisation against PCSK9 in mice bearing melanoma
title Effects of immunisation against PCSK9 in mice bearing melanoma
title_full Effects of immunisation against PCSK9 in mice bearing melanoma
title_fullStr Effects of immunisation against PCSK9 in mice bearing melanoma
title_full_unstemmed Effects of immunisation against PCSK9 in mice bearing melanoma
title_short Effects of immunisation against PCSK9 in mice bearing melanoma
title_sort effects of immunisation against pcsk9 in mice bearing melanoma
topic Experimental Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963136/
https://www.ncbi.nlm.nih.gov/pubmed/32051723
http://dx.doi.org/10.5114/aoms.2020.91291
work_keys_str_mv AT momtaziborojeniamirabbas effectsofimmunisationagainstpcsk9inmicebearingmelanoma
AT nikmaryamebrahimi effectsofimmunisationagainstpcsk9inmicebearingmelanoma
AT jaafarimahmoudreza effectsofimmunisationagainstpcsk9inmicebearingmelanoma
AT banachmaciej effectsofimmunisationagainstpcsk9inmicebearingmelanoma
AT sahebkaramirhossein effectsofimmunisationagainstpcsk9inmicebearingmelanoma